A Phase 1, Single Centre, Three-part, Randomised, Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Multiple Ascending Doses of Oral ONO-4053 and the Effects of Food in Healthy Males and Females.
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2012
At a glance
- Drugs ONO 4053 (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Mar 2012 Actual initiation date changed from 1 Feb 2012 to 1 Jan 2012 as reported by ClinicalTrials.gov.
- 06 Mar 2012 Planned number of patients changed from 136 to 120 as reported by ClinicalTrials.gov.